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There are a lot of techniques that can be used to assessThe use of mesenchymal stem cells/mesenchymal stromal
cells (MSCs) in regenerative medicine is increasing through-
out the world. These cells can easily be isolated from different
tissues and expanded in vitro to produce a sufﬁcient number
of cells that do not have infusion-related toxicity in humans
during cell therapy. Moreover, they have the ability of multi-
lineage differentiation and secrete ‘therapeutic’ factors that
possess trophic, immunomodulatory, and anti-inﬂammatory
activities and are unable to form teratomes.1 Today, due to
these characteristics, there are 385 MSC-based clinical trials
registered at ClinicalTrials.gov, a service provided by the U.S.
National Institutes of Health (www.clinicaltrials.gov).
However, there are substantial ambiguities and uncertain-
ties in the literature concerning the genetic stability of these
cells during in vitro expansion, and before implantation in the
patient.2,3 The reported ex vivo spontaneous malignant trans-
formation of MSCs is limited to only two scientiﬁc articles,4,5
with other authors reporting no tumor formation after in vitro
manipulation, but stating that culture expansion induces
recurrent genomic alterations, mainly aneuploidies, which
rapidly accumulate in cultures. Thus, it is important to mon-
itor the integrity of MSCs before their clinical use.2,6–10 Other
researchers did not ﬁnd genetic alterations and say that if they
do happen they will disappear during culture propagation and
will not have any growth advantage in vitro and thus will not
be a problem in clinical application, thereby concluding that
MSCs have low risk of tumorigenicity.3,11–16
One of the articles published this year in the Revista
Brasileira de Hematologia e Hemoterapia contributes to this
discussion.17 The article entitled “Genetic evaluation of mes-
enchymal stem cells through G-band karyotyping in a Cell
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reserved.Technology Center” shows the G-band cytogenetic method-
ology performed at the Pontifícia Universidade Católica do
Paraná (PUCPR) and the results of the ﬁrst three years of
genetic evaluation of MSC derived from the bone marrow of 21
patients. The main adaptations made by Borgonovo et al.17 to
achieve G-banded chromosomes from MSCs were: adjusting
the time of colcemid action (from 2 to 6h), using additional
washes with higher concentrations of acetic acid in the ﬁx-
ative solution (2 methanol: 1 acetic acid), and alterations in
the trypsin concentration (at least 0.002 g/mL) and time of
exposure (from 5 to 20 s). On analyzing the cells before and
after cell expansion at least until the second passage (P2),
the authors concluded that the cells are chromosomically
stable as no clonal alterations were found. However, they
reported the presence of some signs of chromosomal insta-
bility (chromatid gaps and breaks, and tetraploidy) suggesting
that “long term cultivation could provide an intermediate step
for tumorigenesis”.17
This is an important Brazilian initiative that must be
taken into account in all Cell Technology Centers; this kind
of article leads us to think about some speciﬁc issues about
the genetic evaluation of MSCs and the need for discussion,
harmonization and regulatory points. By analyzing the arti-
cles concerning the genetic stability of MSCs, it highlights
the existence of several variables such as cell origin, use
of different protocols to isolate and expand MSCs, time of
expansion and techniques used to analyze the stability.– LBMG, Universidade Federal do Rio Grande do Norte – UFRN, Av.
genetic stability of MSCs, including conventional karyotyping,
spectral karyotyping (SKY), ﬂuorescent in situ hybridiza-
tion (FISH), genome-wide array comparative genomic
e Terapia Celular. Published by Elsevier Editora Ltda. All rights
er. 20
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ybridization (aCGH), cytokinesis-block micronucleus
ssay (CBMN), microsatellite genotyping, single nucleotide
olymorphism detection, RNA sequencing and detecting
hromosomal aberrations based on gene expression patterns
f these cells.4–19 Each one of these methodologies has
ts degree of accuracy, sensitivity and limitations. These
ariations suggest an inexistence of regulation. The Euro-
ean Regulatory Authorities proposed that conventional
aryotypes should be analyzed to ensure the safety of MSC
roduction, and that aCGH or FISH are only necessary when
ecurrent abnormalities are found.20
In Brazil, the National Agency for Sanitary surveillance
ANVISA) published a resolution in 2011 that says that
Genetic control should be performed in stem cells when they
re cultured and expanded in vitro or genetically modiﬁed”.
owever, there is no speciﬁcation of the method to be used
nd several questions arise such as: How many metaphases
hould be analyzed? What is the quality of the chromosomes
hat should be considered? What kind of alteration should be
onsidered ‘dangerous’, not random nor related to method-
logical problems? Should the criteria determined in the
nternational System of Cytogenetic Nomenclature (ISCN)
elated to abnormalities commonly seen in neoplasias be
he same for MSCs? Are cytogenetic alterations randomly
cquired after the in vitro expansion of MSCs or are speciﬁc
hromosomes more prone to instability in MSCs? The human
aryotype analysis requires extensive personnel training.
urrently, in Brazil most cytogenetic tests are conducted
ithin hospitals, and accreditations and validation that a
esting laboratory should obtain to ensure the validity of the
ytogenetic results do not exist. The scientiﬁc and clinical
ommunity must discuss and try to determine these aspects,
s MSCs are already being used in regenerative medicine and,
ometimes, sold as therapeutic products.
Ben-David et al.7 presented a comprehensive analysis
f chromosomal aberrations in 144 samples of MSCs and
ound that common aberrations in MSC cultures resembled
haracteristic aberrations of mesenchymal tumors, such as
onosomy 13 (with downregulation of the retinoblastoma
umor suppressor gene – RB1) that was recurrent in indepen-
ent studies of MSC cultures and is a common monosomy
n bone and soft tissue tumors.21 The associations can imply
hat speciﬁc aberrations at least confer growth advantage in a
ell lineage-speciﬁc manner, both for stem cells in vitro and
umors in vivo, or may indicate the beginning of a sponta-
eous transformation in culture.2 On the other hand, Tarte
t al.12 identiﬁed, by conventional cytogenetic analysis, donor-
ependent chromosomal abnormalities in ﬁve out of 20 MSC
ultures isolated from bone marrow, including trisomies of
hromosomes 5, 8 and 20, that disappeared in almost all
ultures at P2. Trisomies of chromosomes 5, 7 and 9were iden-
iﬁed in two out of seven MSC samples analyzed by Redaelli
t al.22 Both teams of researchers concluded that negative
election of aneuploid clones might occur in later passages,
ndicating a general chromosomal stability of MSCs. However,
hat calls attention is that the authors did not discuss theact that trisomies of chromosomes 5, 7 and 20 are frequently
ound in myeloid and lymphoid malignancies and both origi-
ate from the leukemogenesis process that takes place in the
one marrow.2114;36(4):238–240 239
Another important point to consider in stem cell therapy
is the genetic stability of these cells after cryopreservation.
Cryopreservation is necessary when the use of these cells will
not occur immediately after their isolation, and so banks of
MSCs are being created all around the world, but the research
on chromosome instability is not proportional to this increase.
Almost 2300 studies were performed with cryopreservation
related to stem cells but themajority of them look at themain-
tenance of stem cell properties (http://www.ncbi.nlm.nih.gov/
pmc/?term=cryopreservation+stem+cell by 03/13/2014). Only
ﬁve articles were found addressing the question of MSC cyto-
genetic instability (http://www.ncbi.nlm.nih.gov/pubmed/?
term=mesenchymal+stem+cell+cytogenetic+cryopreservation
by 03/13/2014). Our group wrote one of these articles,23 and
similar to the results obtained by Borgonovo et al.,17 we found
non-clonal chromosomal alterations in MSCs derived from
the umbilical cord vein after cryopreservation. We believe it
is important to describe them because they are correlated
to overall genetic instability. Of the other articles, only one
described a non-clonal chromosomal alteration,24 but there
are a lot of differences between all these papers, making
it difﬁcult to directly compare the results. The variables
involved are the origins of the MSCs, the method of cryopres-
ervation, time of conservation and number and quality of
metaphases analyzed. In addition, there was no description
of the criteria used to determine chromosomal alterations.
The methods of cryobanking of human stem cells are not
fully deﬁned, which is particularly critical for the umbilical
cord cryopreservation process where the cells will be stored
for an indeterminate time span; at least G-band chromosome
analysis should be performed for each sample after thawing
and before implanting the cells into patients.
In conclusion, we agree with Borgonovo et al.17 and con-
ﬁrm conventional karyotyping as an useful and valuable tool
to analyze chromosomal stability during in vitro expansion
of MSCs. Complementary molecular cytogenetic techniques
such as FISH and aCGH could be used to help to detect low
mosaicism and to increase the sensitivity of genetic stability
analysis. It is important to establish the biosafety proﬁle of
MSCs prepared for use in regenerative medicine, in particular
it is necessary to identify and deﬁne culture conditions dur-
ing in vitro MSC expansion, in order to avoid the occurrence of
chromosomal abnormalities.
The importance and applicability of MSCs is undeniable;
however their biological characteristics must be well studied
and the risk-beneﬁt ratio linked to their clinical use must be
well deﬁned. Rules must be established to standardize the
genetic stability analysis and guarantee better biosafety with
the use of these cells.
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